MNBIO

MNBIO is a South Korean biotechnology company specializing in advanced liquid biopsy technologies for cancer diagnosis and monitoring. The company's core expertise lies in the isolation and analysis of Circulating Tumor Cells (CTCs) using its proprietary microfluidic platform. MNBIO's technology enables high-purity, high-yield recovery of rare cells from blood samples, facilitating downstream molecular characterization and personalized medicine. Their solutions are designed to support early cancer detection, treatment response monitoring, and minimal residual disease (MRD) assessment. The company aims to provide a non-invasive alternative to traditional tissue biopsies, enhancing the management of various solid tumors. By capturing a broad spectrum of CTCs, including those with low EpCAM expression, MNBIO provides a more comprehensive view of tumor heterogeneity.